BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8572619)

  • 1. Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer.
    Boerman OC; Tibben JG; Massuger LF; Claessens RA; Corstens FH
    Anticancer Res; 1995; 15(5B):2169-74. PubMed ID: 8572619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients.
    Tibben JG; Boerman OC; Massuger LF; Schijf CP; Claessens RA; Corstens FH
    Int J Cancer; 1996 May; 66(4):477-83. PubMed ID: 8635863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of anti-CD3 and anti-CD16 bispecific monoclonal antibodies for the targeting of T and NK cells against tumor cells.
    Ferrini S; Cambiaggi A; Sforzini S; Canevari S; Mezzanzanica D; Colnaghi MI; Moretta L
    Cancer Detect Prev; 1993; 17(2):295-300. PubMed ID: 8402715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
    van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
    Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.
    Andersson H; Lindegren S; Back T; Jacobsson L; Leser G; Horvath G
    Anticancer Res; 2000; 20(1A):459-62. PubMed ID: 10769696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
    Negri DR; Tosi E; Valota O; Ferrini S; Cambiaggi A; Sforzini S; Silvani A; Ruffini PA; Colnaghi MI; Canevari S
    Br J Cancer; 1995 Oct; 72(4):928-33. PubMed ID: 7547242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies.
    Boerman O; Massuger L; Makkink K; Thomas C; Kenemans P; Poels L
    Anticancer Res; 1990; 10(5A):1289-95. PubMed ID: 2241105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
    Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
    J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
    Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
    van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
    J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival.
    Miotti S; Negri DR; Valota O; Calabrese M; Bolhuis RL; Gratama JW; Colnaghi MI; Canevari S
    Int J Cancer; 1999 Feb; 84(1):62-8. PubMed ID: 9988234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.
    Bolhuis RL; Lamers CH; Goey SH; Eggermont AM; Trimbos JB; Stoter G; Lanzavecchia A; di Re E; Miotti S; Raspagliesi F
    Int J Cancer Suppl; 1992; 7():78-81. PubMed ID: 1428412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.
    Bortoletto N; Scotet E; Myamoto Y; D'Oro U; Lanzavecchia A
    Eur J Immunol; 2002 Nov; 32(11):3102-7. PubMed ID: 12385030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization.
    Casalini P; Luison E; Ménard S; Colnaghi MI; Paganelli G; Canevari S
    J Nucl Med; 1997 Sep; 38(9):1378-81. PubMed ID: 9293791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis.
    Knogler K; Grünberg J; Zimmermann K; Cohrs S; Honer M; Ametamey S; Altevogt P; Fogel M; Schubiger PA; Novak-Hofer I
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):603-11. PubMed ID: 17255283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.